Defense Advanced Research Projects AgencyTagged Content List

Chemistry

The identification and transformation of substances

Showing 6 results for Chemistry + Therapy RSS
03/01/2018
When a Service member suffers a traumatic injury or acute infection, the time from event to first medical treatment is usually the single most significant factor in determining the outcome between saving a life or not. First responders must act as quickly as possible, first to ensure a patient’s sheer survival and then to prevent permanent disability. The Department of Defense refers to this critical, initial window of time as the “golden hour,” but in many cases the opportunity to successfully intervene may extend much less than sixty minutes, which is why the military invests so heavily in moving casualties as rapidly as possible from the battlefield to suitable medical facilities.
09/11/2019
In the wake of the Iraq and Afghanistan wars, the mental health crisis among U.S. military veterans remains unrelenting, despite the best efforts of healthcare researchers and providers to confront the scale and scope of the problem. According to a 2018 report from the Department of Veterans Affairs, an average of twenty U.S. veterans commit suicide each day.
March 20, 2018,
Webinar
DARPA’s Biological Technologies Office is hosting an online-only Proposers Day webinar to provide information to potential applicants on the structure and objectives of the new Biostasis program. Biostasis aims to extend the time for lifesaving medical treatment following traumatic injury or acute infection by developing novel, non-thermal, molecular interventions to reversibly slow and/or pause the functions of living cells and preserve their viability.
The Biostasis program aims to extend the time for lifesaving medical treatment, often referred to as “the Golden Hour,” following traumatic injury or acute infection, thus increasing survivability for military personnel operating in far-forward conditions with limited access to medical professionals or trauma centers. To do so, Biostasis is developing novel chemical biology approaches that reversibly and controllably slow biological systems without cold-chain to stabilize and protect their functional capacity until medical intervention is possible.
Program Manager
Dr. Amy Jenkins joined DARPA as a program manager in the Biological Technologies Office (BTO) in June 2019. Her interests include the development of platforms for combatting infectious disease threats as well as novel manufacturing methods to enable rapid response.